Hypermarcas (OTCMKTS:HYPMY) Trading Down 4.3% - Should You Sell?

Hypermarcas (OTCMKTS:HYPMY - Get Free Report)'s stock price was down 4.3% during mid-day trading on Thursday . The stock traded as low as $4.50 and last traded at $4.50. Approximately 3,692 shares traded hands during trading, a decline of 79% from the average daily volume of 17,270 shares. The stock had previously closed at $4.70.

Hypermarcas Stock Up 5.4%

The company has a market cap of $3.07 billion, a P/E ratio of 20.21 and a beta of 0.79. The company has a 50 day moving average of $4.33 and a 200-day moving average of $3.61. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.26 and a quick ratio of 0.80.

Hypermarcas (OTCMKTS:HYPMY - Get Free Report) last issued its quarterly earnings results on Wednesday, April 23rd. The company reported ($0.04) earnings per share (EPS) for the quarter. The firm had revenue of $184.34 million for the quarter. Hypermarcas had a return on equity of 6.95% and a net margin of 12.51%.

Hypermarcas Dividend Announcement

The business also recently disclosed a dividend, which will be paid on Friday, January 8th. Stockholders of record on Tuesday, July 1st will be paid a dividend of $0.0345 per share. The ex-dividend date is Monday, June 30th. This represents a dividend yield of 2.81%. Hypermarcas's dividend payout ratio (DPR) is currently 45.83%.

About Hypermarcas

Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.